2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T429,A total of 689 participants were randomized in a 1:1 ratio to brolucizumab, 6 mg (n = 347), or PRP (n = 342), and 572 randomized participants completed the week 54 visit. Mean (SD) patient age was 53.9 (11.39) years, 276 patients (40.1%) were female, and mean (SD) BCVA (letter score) at baseline was 77.1 (10.55) (Snellen equivalent, 20/32). Brolucizumab, 6 mg, was noninferior and superior to PRP for BCVA change at week 54 (least-squares mean [SE] change in letter score: 0.2 [0.72] vs -4.2 [0.73]; difference, 4.4; 95% CI, 2.4-6.4; P < .001). A higher proportion of patients receiving brolucizumab, 6 mg, had no PDR at week 54 vs patients receiving PRP (187 [63.6%] vs 65 [22.4%]; difference, 39.4; 95% CI, 32.0-46.8; P < .001). Ocular adverse events were reported in 119 patients (34.3%) and 168 patients (49.1%) in the brolucizumab, 6 mg, arm and PRP arm, respectively. The rate of intraocular inflammation, including retinal vasculitis, was 18 of 347 patients (5.2%) in the brolucizumab, 6 mg, arm and 2 of 342 patients (0.6%) in the PRP arm.31:Tae3,CONDOR (Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy) is a large-scale, company-sponsored randomized clinical trial to assess the unique 6-week (loading) and 12-week (maintenance) brolucizumab dosing regimen in proliferative diabetic retinopathy (PDR). To assess the efficacy and safety of brolucizumab, 6 mg, compared with panretinal laser photocoagulation (PRP) in eyes with PDR. CONDOR is a 96-week, 2-arm, single-masked, multicenter, phase 3 randomized clinical trial conducted across 16 countries at 152 sites. Data were analyzed from December 4, 2020 (first participant first visit), to October 30, 2023 (cutoff date). Patients with diabetes and PDR diagnosis and no previous PRP treatment in the study eye were eligible for inclusion. Patients randomized to receive brolucizumab, 6 mg, received 3 loading doses every 6 weeks, followed by every 12 weeks, with the option from week 48 onward to extend the treatment interval by 6 weeks at a time up to 24 weeks based on disease activity. Patients randomized to PRP received treatment in 1 to 4 sessions up to week 12, followed by additional PRP treatment as needed. The primary outcome measure was change from baseline in best-corrected visual acuity (BCVA) at week 54. Secondary outcomes included change in DR progression, prevention of center-involved diabetic macular edema, change in Diabetic Retinopathy Severity Score levels, and safety. A total of 689 participants were randomized in a 1:1 ratio to brolucizumab, 6 mg (n = 347), or PRP (n = 342), and 572 randomized participants completed the week 54 visit. Mean (SD) patient age was 53.9 (11.39) years, 276 patients (40.1%) were female, and mean (SD) BCVA (letter score) at baseline was 77.1 (10.55) (Snellen equivalent, 20/32). Brolucizumab, 6 mg, was noninferior and superior to PRP for BCVA change at week 54 (least-squares mean [SE] change in letter score: 0.2 [0.72] vs -4.2 [0.73]; difference, 4.4; 95% CI, 2.4-6.4; P < .001). A higher proportion of patients receiving brolucizumab, 6 mg, had no PDR at week 54 vs patients receiving PRP (187 [63.6%] vs 65 [22.4%]; difference, 39.4; 95% CI, 32.0-46.8; P < .001). Ocular adverse events were reported in 119 patients (34.3%) and 168 patients (49.1%) in the brolucizumab, 6 mg, arm and PRP arm, respectively. The rate of intraocular inflammation, including retinal vasculitis, was 18 of 347 patients (5.2%) in the brolucizumab, 6 mg, arm and 2 of 342 patients (0.6%) in the PRP arm. In the CONDOR randomized clinical trial, brolucizumab was superior to PRP in preserving visual acuity and may be a viable treatment alternative to PRP monotherapy for patients with PDR. ClinicalTrials.gov Identifier: NCT04278417.32:T119e, Importance CONDOR (Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy) is a large-scale, company-sponsored randomized clinical trial to assess the unique 6-week (loading) and 12-week (maintenance) brolucizumab dosing regimen in proliferative diabetic retinopathy (PDR). Objective To assess the efficacy and safety of brolucizumab, 6 mg, compared with panretinal laser photocoagulation (PRP) in eyes with PDR. Design, Setting, and Participants CONDOR is a 96-week, 2-arm, single-masked, multicenter, phase 3 randomized clinical trial conducted across 16 countries at 152 sites. Data were analyzed from December 4, 2020 (first participant first visit), to October 30, 2023 (cutoff date). Patients with diabetes and PDR diagnosis and no previous PRP treatment in the study eye were eligible for inclusion. Intervention Patients randomized to receive brolucizumab, 6 mg, received 3 loading doses every 6 weeks, followed by every 12 weeks, with the option from week 48 onward to extend the treatment interval by 6 weeks at a time up to 24 weeks based on disease activity. Patients randomized to PRP received treatment in 1 to 4 sessions up to week 12, followed by additional PRP treatment as needed. Main Outcomes and Measures The primary outcome measure was change from baseline in best-corrected visual acuity (BCVA) at week 54. Secondary outcomes included change in DR progression, prevention of center-involved diabetic macular edema, change in Diabetic Retinopathy Severity Score levels, and safety. Results A total of 689 participants were randomized in a 1:1 ratio to brolucizumab, 6 mg (n = 347), or PRP (n = 342), and 572 randomized participants completed the week 54 visit. Mean (SD) patient age was 53.9 (11.39) years, 276 patients (40.1%) were female, and mean (SD) BCVA (letter score) at baseline was 77.1 (10.55) (Snellen equivalent, 20/32). Brolucizumab, 6 mg, was noninferior and superior to PRP for BCVA change at week 54 (least-squares mean [SE] change in letter score: 0.2 [0.72] vs −4.2 [0.73]; difference, 4.4; 95% CI, 2.4-6.4; P &lt; .001). A higher proportion of patients receiving brolucizumab, 6 mg, had no PDR at week 54 vs patients receiving PRP (187 [63.6%] vs 65 [22.4%]; difference, 39.4; 95% CI, 32.0-46.8; P &lt; .001). Ocular adverse events were reported in 119 patients (34.3%) and 168 patients (49.1%) in the brolucizumab, 6 mg, arm and PRP arm, respectively. The rate of intraocular inflammation, including retinal vasculitis, was 18 of 347 patients (5.2%) in the brolucizumab, 6 mg, arm and 2 of 342 patients (0.6%) in the PRP arm. Conclusions and Relevance In the CONDOR randomized clinical trial, brolucizumab was superior to PRP in preserving visual acuity and may be a viable treatment alternative to PRP monotherapy for patients with PDR. Trial Registration ClinicalTrials.gov Identifier: NCT04278417 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Anti-VEGF: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Anti-VEGF (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Anti-VEGF\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Anti-VEGF\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Anti-VEGF\"}]}}"}}]],["$","$L2f",null,{"title":"Anti-VEGF: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Anti-VEGF — concise summaries and practical next steps.","papers":[{"doi":"10.1016/j.ajo.2026.08.039","pmid":"42669344","title":"Biomaterials in Retinal Surgery: Engineering the Future","journal_title":"American Journal of Ophthalmology","journal_issn":"0002-9394","published_at":"2026-08-30T00:00:00.000Z","url":"https://doi.org/10.1016/j.ajo.2026.08.039","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-03T06:19:53.828Z","updated_at":"2026-09-03T06:19:53.828Z","tags":[{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"brand","value":"PRIMA","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"condition","value":"Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"condition","value":"Geographic Atrophy","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"condition","value":"Macular Telangiectasia Type 2","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"condition","value":"Retinal Detachment","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"generic","value":"ranibizumab","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"modality","value":"Anti-VEGF","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"modality","value":"Encapsulated Cell Therapy","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"modality","value":"Gene Therapy Vector","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"modality","value":"Hyaluronic Acid Hydrogel","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"modality","value":"Retinal Prosthesis","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"modality","value":"RPE Transplant Scaffold","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"modality","value":"Sustained-Release Drug Delivery","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"modality","value":"Vitreous Tamponade Agent","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"warning","value":"Sample size tag reflects the PRIMA trial cohort (n=32) cited within the review, not an overall study enrollment figure; the review itself has no single patient population.","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"warning","value":"The oxime-crosslinked hyaluronic acid hydrogel data are original preclinical findings embedded within a review article, not a standalone controlled study — rabbit model results may not translate directly to humans.","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"warning","value":"The 'PRIMA' brand tag refers to a photovoltaic subretinal implant device, not a pharmaceutical product.","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.08.039","tag_type":"warning","value":"This is a narrative review without systematic methodology (no PRISMA, no pre-specified eligibility, no dual screening); evidence synthesis conclusions should be interpreted with caution.","value_numeric":null}],"summaries":{"what_studied":"This narrative expert review covers current and emerging biomaterials in retinal surgery across five domains: vitreous tamponade agents, retinal prostheses, RPE transplant scaffolds, intraocular drug delivery platforms, and gene therapy vectors — with original preclinical data on an oxime-crosslinked hyaluronic acid vitreous substitute evaluated in rabbits.","key_result":"The PRIMA photovoltaic subretinal implant improved visual acuity in 81% of geographic atrophy patients (26/32) at 12 months; a 44-channel suprachoroidal prosthesis had no device-related serious adverse events at 2.7 years; the authors' hyaluronic acid hydrogel showed a density of 1.01 g/mL, refractive index of 1.356, and IOP of 13.5–25.9 mmHg with preserved ERG in rabbits; 2025 saw approval of a refillable ranibizumab port delivery system for diabetic retinopathy and the first encapsulated cell therapy implant for macular telangiectasia type 2.","limitations":"The hydrogel vitreous substitute data are preclinical (rabbit model) only; RPE scaffold trials remain in early Phase I/IIa; the review did not use systematic methodology (no PRISMA, no dual screening, no protocol registration), limiting evidence synthesis rigor.","practice_takeaway":"Clinicians should be aware that retinal biomaterial innovation — from subretinal implants to sustained-release drug systems — is moving from stabilization toward tissue replacement, with several recent regulatory approvals and ongoing Phase 3 gene therapy trials reshaping the treatment landscape. Long-term safety, immunogenicity of allogeneic constructs, and scalable manufacturing remain unresolved before wider clinical adoption."}},{"doi":"10.1186/s12886-026-05199-5","pmid":"42638100","title":"Sympathetic ophthalmia complicating proliferative diabetic retinopathy: diagnostic and therapeutic challenges during pregnancy","journal_title":"BMC Ophthalmology","journal_issn":"1471-2415","published_at":"2026-08-24T00:00:00.000Z","url":"https://doi.org/10.1186/s12886-026-05199-5","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-02T06:22:41.110Z","updated_at":"2026-09-02T06:22:41.110Z","tags":[{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"condition","value":"Proliferative Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"condition","value":"Sympathetic Ophthalmia","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"condition","value":"Type 1 Diabetes Mellitus","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"condition","value":"Uveitis","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"generic","value":"methylprednisolone","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"generic","value":"prednisolone","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"modality","value":"Anti-VEGF","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"modality","value":"Corticosteroid","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"modality","value":"Panretinal Photocoagulation","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"modality","value":"Pars Plana Vitrectomy","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"warning","value":"Adalimumab continuation into the third trimester was individualized given monocular status; this deviates from some guideline recommendations and should not be applied routinely.","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"warning","value":"Multiple confounding factors (SO, PDR, poor glycemic control, two pregnancies) coexist, making causal attribution of outcomes to any single intervention uncertain.","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"warning","value":"The Humira brand tag is inferred from adalimumab use; the paper does not specify the brand name explicitly.","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"warning","value":"This is a single case report (n=1); findings should not be generalized to broader clinical practice without corroborating evidence.","value_numeric":null}],"summaries":{"what_studied":"A single case of a 27-year-old woman with poorly controlled type 1 diabetes who developed sympathetic ophthalmia (SO) in the fellow eye 10 weeks after penetrating ocular injury repair, with coexisting proliferative diabetic retinopathy (PDR) and a concurrent second pregnancy, managed with IV methylprednisolone, oral prednisolone taper, adalimumab, augmented panretinal photocoagulation (PRP), and postpartum pars plana vitrectomy.","key_result":"Visual acuity improved from 20/100 to 20/25 after systemic immunosuppression and augmented PRP, with partial regression of neovascularization; following postpartum vitrectomy for recurrent vitreous hemorrhage and tractional retinal detachment, final VA was 20/40 with inactive uveitis and a flat, attached retina.","limitations":"Single case report limits generalizability; multiple overlapping variables (SO, PDR, two pregnancies, poor glycemic control) make it impossible to isolate the contribution of each factor; no control or comparator eye with similar combined pathology.","practice_takeaway":"When SO is diagnosed in a patient with PDR, prompt systemic immunosuppression can itself reduce neovascular activity—consider early adalimumab as a steroid-sparing agent to limit corticosteroid-induced hyperglycemia. In pregnant patients, defer intravitreal anti-VEGF when possible, favor PRP, individualize biologic continuation with multidisciplinary input, and plan vitrectomy for the postpartum period unless vision-threatening urgency demands earlier intervention."}},{"doi":"10.1016/j.ophtha.2026.05.007","pmid":"42489607","title":"Anti–VEGF versus Laser Photocoagulation Surgery for Primary Treatment of Retinopathy of Prematurity: Neurodevelopmental Outcomes","journal_title":"Ophthalmology","journal_issn":"0161-6420","published_at":"2026-07-23T00:00:00.000Z","url":"https://doi.org/10.1016/j.ophtha.2026.05.007","source_score":2,"is_retracted":false,"is_open_access":null,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":false},"created_at":"2026-07-27T14:09:19.698Z","updated_at":"2026-07-27T14:09:19.698Z","tags":[{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"age_group","value":"infant","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"age_group","value":"neonate","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"brand","value":"Avastin","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"brand","value":"Lucentis","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"condition","value":"Retinopathy of Prematurity","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"generic","value":"ranibizumab","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"modality","value":"Anti-VEGF","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"modality","value":"Laser Photocoagulation","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"sample_size","value":"n=26","value_numeric":26},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"study_design","value":"Systematic Review","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"warning","value":"Brand tags (Avastin, Lucentis) are inferred from generic names; the paper does not explicitly name these brands.","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"warning","value":"Level of evidence assigned as '2' reflects the best available included studies (RCTs rated level II); the overall systematic review lacks level I evidence and was not meta-analytic.","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"warning","value":"Some studies spanned a wide age range (0 months to 12 years), making pooled neurodevelopmental interpretation heterogeneous.","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.05.007","tag_type":"warning","value":"The sample size tag reflects the number of included studies (n=26), not individual patients — total patient-level N is not reported in the abstract.","value_numeric":null}],"summaries":{"what_studied":"This systematic review compared neurodevelopmental outcomes in premature infants treated with intravitreal anti-VEGF (primarily bevacizumab or ranibizumab) versus laser photocoagulation surgery (LPC) as primary treatment for retinopathy of prematurity (ROP), synthesizing 26 studies (3 RCTs + 22 cohort studies) spanning 2006–2022 across 39 countries.","key_result":"77% of studies (20/26), including all RCTs, found no statistically significant difference in neurodevelopmental outcomes between anti-VEGF and LPC; 4 studies found worse outcomes with intravitreal bevacizumab and 2 found worse outcomes with LPC. None of the 5 studies that included IQ testing beyond age 4 detected a significant difference between treatment groups.","limitations":"No study was powered specifically for neurodevelopmental outcomes, limiting ability to detect small but clinically meaningful differences. Most assessments (54%) were done before age 24 months, and long-term cognitive data (IQ beyond age 4) were available in only 19% of studies. No level I (RCT-powered for neurodevelopment) evidence exists.","practice_takeaway":"Based on current level II–III evidence, neither anti-VEGF nor LPC appears to confer a clear neurodevelopmental advantage for primary ROP treatment. Clinicians should remain cautious about long-term outcomes given sparse data beyond early childhood, and ongoing follow-up of treated infants into school age is warranted."}},{"doi":"10.1080/09273948.2026.2679855","pmid":"42206750","title":"Atypical COQ2-Related Retinopathy in Identical Twins with Nephropathy Mimicking Intermediate Uveitis","journal_title":"Ocular Immunology and Inflammation","journal_issn":"0927-3948","published_at":"2026-05-28T00:00:00.000Z","url":"https://doi.org/10.1080/09273948.2026.2679855","source_score":2,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-07T13:26:38.633Z","updated_at":"2026-06-07T13:26:38.633Z","tags":[{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"brand","value":"Avastin","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"condition","value":"COQ2-Related Retinopathy","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"condition","value":"Cystoid Macular Oedema","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"condition","value":"Focal Segmental Glomerulosclerosis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"condition","value":"Intermediate Uveitis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"condition","value":"Primary Coenzyme Q10 Deficiency","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"generic","value":"acetazolamide","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"generic","value":"coenzyme Q10","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"generic","value":"dorzolamide","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"modality","value":"Anti-VEGF","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"modality","value":"Mitochondrial Supplement","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"sample_size","value":"n=2","value_numeric":2},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"warning","value":"Electrophysiological improvement after CoQ10 supplementation fell within normal test-retest variability; efficacy conclusion is tentative.","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"warning","value":"Only 2 patients reported (identical twins sharing the same variant); phenotypic conclusions are highly preliminary.","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"warning","value":"The Avastin (bevacizumab) brand tag is inferred from context; the paper does not explicitly name the brand formulation used.","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2679855","tag_type":"warning","value":"The bilateral CMO response to unilateral bevacizumab is intriguing but spontaneous fluctuation cannot be ruled out given the small sample.","value_numeric":null}],"summaries":{"what_studied":"This retrospective case report describes two 33-year-old identical male twins with a homozygous COQ2 variant (c.683A>G, p.Asn228Ser) presenting with bilateral cystoid macular oedema (CMO), vitreous cells, and retinal microangiopathy mimicking intermediate uveitis, alongside nephropathy (FSGS) but no neurological involvement.","key_result":"Whole-exome sequencing confirmed primary CoQ10 deficiency type 1; electrophysiology showed severely abnormal EOG with only borderline ERG changes, indicating predominant RPE dysfunction. CMO worsened with topical corticosteroids but improved bilaterally after a single unilateral intravitreal bevacizumab injection. After one year of oral CoQ10 supplementation (10 mg/kg/day, then 5 mg/kg/day), EOG and ERG parameters showed slight but uncertain improvement within test-retest variability.","limitations":"- Only 2 patients (identical twins); findings may not generalize to other COQ2 variants or presentations.\n- Electrophysiological improvement after CoQ10 supplementation was within expected intra-individual test-retest variability (25–40% for ERG, ~10% for EOG), making true benefit unclear.\n- Spontaneous fluctuation cannot be excluded as an explanation for the bilateral CMO response to unilateral bevacizumab.","practice_takeaway":"In young patients with CMO resembling intermediate uveitis—especially when paired with unexplained nephropathy—consider genetic testing for COQ2 and related mitochondrial disorders before initiating corticosteroids, which may worsen CMO. Early CoQ10 supplementation and anti-VEGF therapy (rather than steroids) may be more appropriate in confirmed cases."}},{"doi":"10.1038/s41433-026-04486-1","pmid":"42162248","title":"Infographic: Efficacy and Safety of HighDdose Intravitreal Aflibercept 8 mg in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration: Week 96 Results from the Phase 3 PULSAR Trial","journal_title":"Eye","journal_issn":"0950-222X","published_at":"2026-05-20T00:00:00.000Z","url":"https://doi.org/10.1038/s41433-026-04486-1","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-30T13:22:43.943Z","updated_at":"2026-05-30T13:22:43.943Z","tags":[{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"brand","value":"Eylea HD","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"condition","value":"Neovascular Age-Related Macular Degeneration","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"generic","value":"aflibercept","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"modality","value":"Anti-VEGF","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"study_design","value":"Phase 3 Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"warning","value":"DOI domain '10.1038/s41433-026-04486-1' uses a future year suffix (2026); publication date appears consistent with today's date but the DOI format is unusual — verify when the full paper is indexed.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"warning","value":"Sample size was not reported in the available source text and could not be tagged.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"warning","value":"Sex distribution of the study population is not stated in the available source text.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"warning","value":"Source text is an infographic abstract only — no numerical efficacy or safety data are present, so key results could not be populated with specific figures.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"warning","value":"The comparator arm (e.g., aflibercept 2 mg or other agent) is not specified in the available source text.","value_numeric":null}],"summaries":{"practice_takeaway":"High-dose aflibercept 8 mg is being evaluated as an extended-interval treatment option for treatment-naïve nAMD; clinicians should seek the full PULSAR trial publication for specific efficacy and safety figures before changing practice.","what_studied":"The PULSAR Phase 3 trial evaluated the efficacy and safety of high-dose intravitreal aflibercept 8 mg versus a comparator in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) over 96 weeks.","key_result":"This is an infographic summarizing Week 96 results from the PULSAR trial; specific numerical outcomes (e.g., visual acuity changes, anatomical outcomes) are not provided in the source text beyond the trial identifier and timeframe.","limitations":"Source provided is an infographic abstract only — detailed methodology, full outcome data, subgroup analyses, and adverse event rates are not extractable from the available text."}},{"doi":"10.1038/s41433-026-04564-4","pmid":"42156919","title":"Infographic: Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, Phase 3 trial","journal_title":"Eye","journal_issn":"0950-222X","published_at":"2026-05-19T00:00:00.000Z","url":"https://doi.org/10.1038/s41433-026-04564-4","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-21T13:21:02.444Z","updated_at":"2026-05-21T13:21:02.444Z","tags":[{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"brand","value":"Eylea","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"condition","value":"Neovascular Age-Related Macular Degeneration","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"generic","value":"aflibercept","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"modality","value":"Anti-VEGF","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"warning","value":"Brand tag 'Eylea' is used for aflibercept; the 8 mg formulation (Eylea HD) may be a distinct branded product — clinicians should verify the specific product labeling applicable in their region.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"warning","value":"Sample size could not be confirmed from the provided source and has been omitted.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"warning","value":"This paper is an infographic format, not a full manuscript — granular data (e.g., exact BCVA change values, safety event rates, sample size) are not extractable from the provided metadata alone.","value_numeric":null}],"summaries":{"what_studied":"This Phase 3 randomised, double-masked, non-inferiority trial (PULSAR) evaluated intravitreal aflibercept 8 mg dosed at extended intervals (every 12 or 16 weeks) versus aflibercept 2 mg every 8 weeks in adults with neovascular age-related macular degeneration (nAMD), reporting outcomes at 48 weeks.","key_result":"At 48 weeks, aflibercept 8 mg dosed every 12 or 16 weeks was non-inferior to aflibercept 2 mg every 8 weeks for best-corrected visual acuity gains, supporting extended dosing intervals with the higher-dose formulation.","limitations":"This paper is presented as an infographic, which means full study data, subgroup analyses, and safety details may not be comprehensively reported. Non-inferiority trial design limits ability to detect superiority claims beyond the pre-specified margin.","practice_takeaway":"Aflibercept 8 mg may allow clinicians to extend treatment intervals to every 12–16 weeks in nAMD patients without sacrificing visual acuity outcomes compared to standard 2 mg dosing every 8 weeks. This could meaningfully reduce treatment burden for patients and practices."}},{"doi":"10.1001/jamaophthalmol.2026.1008","pmid":"42024409","title":"Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy","journal_title":"JAMA Ophthalmology","journal_issn":"2168-6165","published_at":"2026-04-23T00:00:00.000Z","url":"https://doi.org/10.1001/jamaophthalmol.2026.1008","source_score":21,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-24","doi":"10.1001/jamaophthalmol.2026.1008","days":"30","issn":"2168-6165","rank":"7","field":"Clinical Medicine","score":"21","category":"Ophthalmology","categories":["Ophthalmology"],"_categories":["Ophthalmology"]},"pubmed":{"doi":"10.1001/jamaophthalmol.2026.1008","title":"Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial.","journal":"JAMA ophthalmology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"42024409","conclusions":"","publication_date":"2026-04-23T00:00:00"},"crossref":{"DOI":"10.1001/jamaophthalmol.2026.1008","URL":"https://doi.org/10.1001/jamaophthalmol.2026.1008","ISSN":["2168-6165"],"link":[{"URL":"https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2847704/jamaophthalmology_wolf_2026_oi_260018_1775569472.28639.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy"],"author":[{"given":"Sebastian","family":"Wolf","sequence":"first","affiliation":[{"name":"Bern Photographic Reading Center, Department of Ophthalmology, University Hospital, University of Bern, Bern, Switzerland"}]},{"given":"Youxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Beijing, China"}]},{"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Medical University, Tianjin, China"}]},{"given":"Masahiko","family":"Shimura","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Bellaire"},{"name":"Retina Consultants of America, Houston, Texas"}]},{"given":"Andres","family":"Emanuelli","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico"}]},{"given":"Hani","family":"Salehi-Had","sequence":"additional","affiliation":[{"name":"Retina Associates of Southern California, Huntington Beach"}]},{"given":"Kang","family":"Yan","sequence":"additional","affiliation":[{"name":"China Novartis Institutes for BioMedical Research Co Ltd, Shanghai, China"}]},{"given":"Lidija","family":"Kovacic","sequence":"additional","affiliation":[{"name":"Novartis AG, Basel, Switzerland"}]},{"given":"Yongsoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Novartis AG, Basel, Switzerland"}]}],"issued":{"date-parts":[[2026,4,23]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-04-23T15:30:36Z","timestamp":1776958236000,"date-parts":[[2026,4,23]]},"indexed":{"date-time":"2026-04-23T15:47:56Z","timestamp":1776959276483,"date-parts":[[2026,4,23]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2847704"}},"subtitle":["The CONDOR Randomized Clinical Trial"],"deposited":{"date-time":"2026-04-23T15:30:37Z","timestamp":1776958237000,"date-parts":[[2026,4,23]]},"issn-type":[{"type":"print","value":"2168-6165"}],"published":{"date-parts":[[2026,4,23]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.3390/life13051098","key":"eoi260018r1","year":"2023","issue":"5","author":"Bahr","volume":"13","first-page":"1098","unstructured":null,"article-title":"Update on the management of diabetic retinopathy: anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy.","journal-title":"Life (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2021.04.027","key":"eoi260018r2","year":"2021","issue":"11","author":"Teo","volume":"128","first-page":"1580","unstructured":null,"article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMct0908432","key":"eoi260018r3","year":"2011","issue":"16","author":"Bressler","volume":"365","first-page":"1520","unstructured":null,"article-title":"Panretinal photocoagulation for proliferative diabetic retinopathy.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1080/08820538.2017.1353820","key":"eoi260018r4","year":"2018","issue":"1","author":"Reddy","volume":"33","first-page":"83","unstructured":null,"article-title":"Panretinal photocoagulation: a review of complications.","journal-title":"Semin Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ajo.2005.02.029","key":"eoi260018r5","year":"2005","issue":"1","author":"Shimura","volume":"140","first-page":"8","unstructured":null,"article-title":"Visual dysfunction after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision.","journal-title":"Am J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2018.04.039","key":"eoi260018r6","year":"2018","issue":"11","author":"Bressler","volume":"125","first-page":"1776","unstructured":null,"article-title":"Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: factors associated with vision and edema outcomes.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaophthalmol.2018.3255","key":"eoi260018r7","year":"2018","issue":"10","author":"Gross","volume":"136","first-page":"1138","unstructured":null,"article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.","journal-title":"JAMA Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.3389/fendo.2023.1144422","key":"eoi260018r8","year":"2023","issue":null,"author":"Xie","volume":"14","first-page":null,"unstructured":null,"article-title":"Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis.","journal-title":"Front Endocrinol (Lausanne)","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(17)31193-5","key":"eoi260018r9","year":"2017","issue":"10085","author":"Sivaprasad","volume":"389","first-page":"2193","unstructured":null,"article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2018.08.001","key":"eoi260018r10","year":"2019","issue":"1","author":"Sun","volume":"126","first-page":"87","unstructured":null,"article-title":"Rationale and application of the protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2019.12.031","key":"eoi260018r11","year":"2020","issue":"7","author":"Nguyen","volume":"127","first-page":"963","unstructured":null,"article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41433-020-0961-6","key":"eoi260018r12","year":"2020","issue":null,"author":"Amoaku","volume":"34","first-page":"1","unstructured":null,"article-title":"Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.","journal-title":"Eye (Lond)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ajo.2022.01.004","key":"eoi260018r13","year":"2022","issue":null,"author":"Brown","volume":"238","first-page":"157","unstructured":null,"article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema.","journal-title":"Am J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2015.15217","key":"eoi260018r14","year":"2015","issue":"20","author":"Gross","volume":"314","first-page":"2137","unstructured":null,"article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1097/MD.0000000000034856","key":"eoi260018r15","year":"2023","issue":"39","author":"Fu","volume":"102","first-page":null,"unstructured":null,"article-title":"Efficacy and safety of pan retinal photocoagulation combined with intravitreal anti-VEGF agents for high-risk proliferative diabetic retinopathy: a systematic review and meta-analysis.","journal-title":"Medicine (Baltimore)","doi-asserted-by":"publisher"},{"DOI":"10.1097/ICU.0000000000000799","key":"eoi260018r16","year":"2021","issue":"6","author":"Nanegrungsunk","volume":"32","first-page":"590","unstructured":null,"article-title":"Prevention of vision-threatening complications in diabetic retinopathy: two perspectives based on results from the DRCR Retina Network Protocol W and the Regeneron-sponsored PANORAMA.","journal-title":"Curr Opin Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2016.12.005","key":"eoi260018r17","year":"2017","issue":"4","author":"Bressler","volume":"124","first-page":"431","unstructured":null,"article-title":"Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1080/08820538.2023.2271095","key":"eoi260018r18","year":"2024","issue":"4","author":"Abu Serhan","volume":"39","first-page":"251","unstructured":null,"article-title":"Safety and efficacy of brolucizumab in the treatment of diabetic macular edema and diabetic retinopathy: a systematic review and meta-analysis.","journal-title":"Semin Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaophthalmol.2023.5248","key":"eoi260018r19","year":"2023","issue":"12","author":"Singh","volume":"141","first-page":"1152","unstructured":null,"article-title":"Efficacy and safety of brolucizumab for diabetic macular edema: the KINGFISHER randomized clinical trial.","journal-title":"JAMA Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2011.12.039","key":"eoi260018r20","year":"2012","issue":"4","author":"Nguyen","volume":"119","first-page":"789","unstructured":null,"article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaophthalmol.2021.2809","key":"eoi260018r21","year":"2021","issue":"9","author":"Brown","volume":"139","first-page":"946","unstructured":null,"article-title":"Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial.","journal-title":"JAMA Ophthalmol","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Ophthalmology"],"reference-count":21,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,23]]},"references-count":21,"short-container-title":["JAMA Ophthalmol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamaophthalmol.2026.1008","is_oa":true,"title":"Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy","updated":"2026-04-27T08:42:52+00:00","published_date":"2026-04-23","best_oa_location":{"url":"https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2847704/jamaophthalmology_wolf_2026_oi_260018_1775569472.28639.pdf","pmh_id":null,"url_for_pdf":"https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2847704/jamaophthalmology_wolf_2026_oi_260018_1775569472.28639.pdf","url_for_landing_page":"https://doi.org/10.1001/jamaophthalmol.2026.1008"}}},"created_at":"2026-05-07T22:49:15.666Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"brand","value":"Beovu","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"condition","value":"Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"condition","value":"Proliferative Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"generic","value":"brolucizumab","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"modality","value":"Anti-VEGF","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"sample_size","value":"n=689","value_numeric":689},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"warning","value":"Brand name 'Beovu' used for brolucizumab; confirm regulatory approval status for PDR indication in relevant jurisdiction before clinical use.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"warning","value":"Single-masked design (investigator-masked, not patient-masked) limits blinding rigor for subjective endpoints like BCVA.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"warning","value":"The article DOI references a 2026 publication date, which is ahead of conventional indexing; results should be verified upon formal publication.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"warning","value":"The trial is company-sponsored, which may introduce bias in outcomes reporting or design choices.","value_numeric":null}],"summaries":{"what_studied":"The CONDOR phase 3 RCT compared intravitreal brolucizumab 6 mg (loading every 6 weeks × 3, then every 12 weeks, with optional extension to 24 weeks) vs. panretinal photocoagulation (PRP) in 689 treatment-naive PDR patients across 152 sites in 16 countries over 96 weeks, with the primary endpoint at week 54.","key_result":"Brolucizumab was superior to PRP for BCVA change at week 54 (+0.2 vs. −4.2 letters; difference 4.4 letters, 95% CI 2.4–6.4; P < .001). PDR resolution occurred in 63.6% of brolucizumab patients vs. 22.4% of PRP patients. However, intraocular inflammation (including retinal vasculitis) occurred in 5.2% of brolucizumab patients vs. 0.6% with PRP.","limitations":"- Single-masked design (patients could not be blinded to treatment arm), which may introduce bias in subjective outcomes.\n- Company-sponsored trial raises potential for industry bias.\n- 96-week trial data beyond week 54 (the primary endpoint cutoff) are not yet fully reported here.","practice_takeaway":"Brolucizumab preserves vision better than PRP monotherapy in PDR, but clinicians should counsel patients on a meaningful intraocular inflammation risk (~5%), including retinal vasculitis, before choosing it over laser. It may be a viable PRP alternative, particularly for patients at risk of vision loss from laser-related side effects."}}],"initialOffset":7,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Anti-VEGF"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Anti-VEGF"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Anti-VEGF"}}}]]

Papers